Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.
Chemomab Therapeutics Ltd. (CMMB) generates news primarily as a clinical-stage biotechnology company developing nebokitug, a monoclonal antibody targeting the soluble protein CCL24 in fibro-inflammatory diseases. Much of the company’s news flow centers on clinical data, regulatory interactions and scientific presentations related to primary sclerosing cholangitis (PSC), a rare and progressive liver disease with no effective medical therapy other than liver transplantation in advanced cases.
Investors and observers following Chemomab news can expect detailed updates on the Phase 2 SPRING trial of nebokitug in PSC, including results from the double-blind, placebo-controlled portion and the open label extension, where patients received nebokitug for up to 48 weeks. Press releases describe safety and tolerability findings, changes in biomarkers such as ELF score, PRO-C3 and liver stiffness measurements, and analyses in subgroups with moderate or advanced fibrosis. These reports often highlight biomarker patterns that are associated with PSC disease progression and transplant-free survival.
Chemomab’s news also covers regulatory milestones, such as outcomes of End-of-Phase 2 meetings with the FDA, alignment on a single Phase 3 registration trial design using a composite of clinically relevant events, and agreements on Chemistry, Manufacturing and Controls (CMC) and nonclinical toxicology requirements. Additional announcements address Orphan Drug and Fast Track designations for nebokitug, as well as the status of an open U.S. IND for systemic sclerosis.
Another recurring theme in Chemomab’s news releases is its scientific and investor outreach. The company reports oral and poster presentations at major liver and gastroenterology meetings, including Digestive Disease Week, BSG Live, AASLD The Liver Meeting and EASL congresses, where nebokitug data and CCL24-related mechanisms are discussed. Chemomab also announces participation in rare disease summits and global investment conferences, along with corporate updates tied to quarterly financial results, patent awards and capital markets activities such as at-the-market equity offerings or ADS ratio adjustments.
Readers of the CMMB news page on Stock Titan can use this stream of clinical, regulatory and corporate announcements to track Chemomab’s progress with nebokitug in PSC and other fibro-inflammatory indications, as well as to monitor key events that may influence the company’s development plans and regulatory trajectory.
Chemomab Therapeutics, a clinical-stage biotech company focused on fibro-inflammatory diseases, will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023. The conference will be held virtually, with the presentation scheduled for 9:20 am ET. Investors can also request 1-on-1 meetings with management through Oppenheimer representatives. Chemomab is advancing its lead product, CM-101, targeting fibrosis and inflammation. Recent developments include completing a Phase 2 liver fibrosis biomarker study and preparing for a Phase 2 trial in systemic sclerosis in the first half of 2023. More details are available at investors.chemomab.com/events.
Chemomab Therapeutics (CMMB) received FDA clearance for the Phase 2 ABATE trial to evaluate CM-101 in patients with systemic sclerosis (SSc). The trial aims to assess safety and establish proof-of-concept for CM-101, a monoclonal antibody targeting fibrosis in SSc. CM-101 has shown promise in preclinical studies, reducing fibrotic injury in affected organ systems. The ABATE trial targets 45 patients and emphasizes safety as its primary endpoint, with results anticipated in the second half of 2024. CM-101 is positioned to potentially become the first disease-modifying treatment for SSc, a condition affecting approximately 100,000 patients in the U.S.
Chemomab Therapeutics (CMMB) announced positive results from its Phase 2a trial of CM-101 in NASH patients. The trial met its primary endpoint of safety and tolerability, with most adverse events being mild. CM-101 demonstrated significant reductions in liver fibrosis biomarkers, with nearly 60% of treated patients improving in three or more biomarkers. The trial included 23 patients receiving either CM-101 or placebo over 16 weeks. These findings reinforce Chemomab's ongoing optimism for CM-101's potential in treating fibrotic diseases.
Chemomab Therapeutics (Nasdaq: CMMB) announced a positive safety review from an independent Data Monitoring Committee for its ongoing Phase 2 trial of CM-101 in patients with primary sclerosing cholangitis (PSC). The DMC found no safety concerns in advancing to a higher dose cohort of 20 mg/kg, alongside the current 10 mg/kg dosing. CM-101, a monoclonal antibody targeting CCL24, aims to treat fibrotic and inflammatory diseases. Top-line results from this PSC trial are expected in H2 2024, with additional insights from a separate liver fibrosis biomarker trial anticipated soon.
Chemomab Therapeutics (Nasdaq: CMMB) has appointed Mitchell L. Jones, MD, PhD, as Vice President of Corporate Development & Strategy. Dr. Jones's expertise spans over 15 years in biopharmaceuticals, focusing on clinical development and corporate strategy. He previously held key roles at Nasdaq-listed companies Finch Therapeutics and Biora Therapeutics. Dr. Jones aims to advance Chemomab's CM-101 product, targeting fibrotic and inflammatory diseases. This move is seen as a strategic enhancement for Chemomab's leadership as it progresses through clinical trials.
Chemomab Therapeutics (Nasdaq: CMMB) reported its Q3 2022 financial and operational results, revealing a net loss of $8.1 million, up from $3.0 million in Q3 2021. Cash reserves stood at $46.5 million, expected to sustain operations through year-end 2023. Key developments include progression in clinical trials for CM-101, with imminent results from the liver fibrosis trial in NASH patients. The company is also advancing a Phase 2 trial in systemic sclerosis, targeting 60 patients, and has opened additional sites in Europe and the U.S. for ongoing studies.
Chemomab Therapeutics (Nasdaq: CMMB) has presented new clinical data indicating that CM-101, a monoclonal antibody, is safe and well-tolerated in patients with COVID-19-derived lung injury. The study, conducted on 16 hospitalized patients, showed significant reductions in lung inflammation and fibrogenesis biomarkers. Key findings included a 65% reduction in CXCL10 levels within 24 hours and a 50% decrease in C-reactive protein (CRP) after 48 hours. CM-101 aims to treat inflammatory and fibrotic diseases, with ongoing Phase 2 trials for primary sclerosing cholangitis and systemic sclerosis.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) will announce its third quarter 2022 financial results on November 11, 2022, at 8:00 am Eastern Time. The event will include a review of performance, recent developments, and a live Q&A session. The company is focused on developing therapeutics for fibrotic and inflammatory diseases, with its lead product, CM-101, in Phase 2 trials for conditions including liver fibrosis. A replay of the call will be available on the company’s website for 90 days following the event.
Chemomab Therapeutics Ltd (Nasdaq: CMMB), a clinical-stage biotechnology company, announced its participation in key scientific conferences in November 2022. Notably, it will present a poster on CCL24 Blockade at the AASLD - The Liver Meeting from November 4-8, and an oral presentation on CM-101 at the Union World Conference on Lung Health from November 8-11. These presentations aim to showcase advancements in therapeutics for fibrotic and inflammatory diseases.
Chemomab Therapeutics (CMMB) reported its Q2 2022 financial results, highlighting significant progress in its clinical programs, particularly CM-101, a monoclonal antibody targeting fibrosis and inflammation. The company concluded the treatment phase of a Phase 2 trial for liver fibrosis in NASH patients, with topline results expected by year-end. Chemomab also received a U.S. patent for CM-101 in liver diseases, extending its protection until at least 2038. Financially, the company had $51.8 million in cash, with a net loss of $6.2 million for the quarter.
FAQ
What is the current stock price of Chemomab Therapeutics (CMMB)?
What is the market cap of Chemomab Therapeutics (CMMB)?
